Virtual Hot Seat™: Experts Face Key Questions to Maximize the Use of PI3K Inhibitors Across Hematologic Malignancies

Release Date: December 15, 2021
Expiration Date: December 15, 2022

Activity Overview

Acknowledgement of Commercial Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Secura Bio, Inc., and TG Therapeutics, Inc.
 

Target Audience

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Discuss mechanistic rationale supporting the role of PI3K inhibition in the management of hematologic malignancies, such as CLL and lymphomas
• Review the evidence from recent and key clinical trials highlighting the role of PI3K inhibitors in the treatment of patients with hematologic malignancies
• Evaluate potential implications of emerging data as well as planned/ongoing trials evaluating current and investigational PI3K inhibitors in the management of patients with hematologic malignancies
• Implement strategies to personalize and optimize treatment with PI3K inhibition in hematologic malignancies including early recognition, proactive mitigation, as well as effective management of treatment-related toxicities

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies. 

 

Chair

Javier Pinilla-Ibarz, MD, PhD
Senior Member
Head of Lymphoma Section
Director of Immunotherapy
Department of Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
Professor, Department of Oncologic Sciences
Morsani College of Medicine
University of South Florida
Tampa, FL
 

Catherine C. Coombs, MD
Assistant Professor of Medicine
Department of Medicine
Division of Hematology
University of North Carolina at Chapel Hill
Chapel Hill, NC
 

Disclosures: Grant/Research Support (for trials): LOXO Oncology, H3 Biomedicine; Consultant: AbbVie, Genetech, AstraZeneca, BeiGene, LOXO Oncology at Lilly, Novartis, MEI Pharma; Speaker’s Bureau: AbbVie

Francine Foss, MD
Professor of Medicine
Hematology and Cell Therapy
Yale University School of Medicine
New Haven, CT
 

Disclosures: Consultant: Secura Bio

Nathan H. Fowler, MD
Professor, Department of Lymphoma-Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
 

Disclosures: Grant/Research Support: Roche, Celgene, Bristol Myers Squibb, Gilead, TG Therapeutics; Consultant: Gilead, TG Therapeutics 

Caron A. Jacobson, MD, MMSc
Medical Director, Immune Effector Cell Therapy Program
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
 

Disclosures: Gran/Research Support: Kite/Gilead, Pfizer; Consultant: Kite/Gilead, Novartis, Bristol Myers Squibb/Celgene, Nkarta, bluebird bio, Epizyme, Lonza, AbbVie, Ipsen
 

Nitin Jain, MD
Associate Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
 

Disclosures: Grant/Research Support: Pharmacyclics, AbbVie, Genentech, AstraZeneca, Bristol Myers Squibb, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Adaptive Biotechnologies, Precision BioSciences, Aprea Therapeutics, Fate Therapeutics; Consultant: Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Adaptive Biotechnologies, Servier, Precision BioSciences, BeiGene, TG Therapeutics, ADC Therapeutics 

Joanna M. Rhodes, MD, MSCE
Assistant Professor
CLL Research and Treatment Program
Northwell Health Cancer Institute
Donald and Barbara Zucker SOM at Hofstra/Northwell
New Hyde Park, NY
 

Disclosures: Consultant: AbbVie, Genentech, PYC Therapeutics, TG Therapeutics, AstraZeneca, BeiGene, Verastem Oncology, Seagen

 

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.